Stay updated on Zolbetuximab in CLDN18.2+ Gastric Cancer Clinical Trial
Sign up to get notified when there's something new on the Zolbetuximab in CLDN18.2+ Gastric Cancer Clinical Trial page.

Latest updates to the Zolbetuximab in CLDN18.2+ Gastric Cancer Clinical Trial page
- Check7 days agoChange DetectedThe page now displays revision v3.6.5, replacing the previous v3.6.4, indicating a version update of the study details page.SummaryDifference0.0%

- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedThe revision label was updated from v3.6.3 to v3.6.4, indicating a new release version without altering the displayed study details.SummaryDifference0.0%

- Check35 days agoChange DetectedAdded a new PubMed publication entry for Shitara et al. on first-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma. The citation shows Nat Med 2026 Jun;32(6):2182-2190 with an Epub date of 2026 Mar 16, replacing the earlier Online ahead of print note.SummaryDifference0.0%

- Check49 days agoChange DetectedRevision tag updated to v3.6.3, replacing the previous v3.6.0 on the page. This indicates a new site revision without altering study details.SummaryDifference0.0%

- Check56 days agoChange DetectedThe study milestone dates were updated to Primary Completion: 2026-12-31 and Study Completion: 2027-11-30, with the last update posted on 2026-06-18, reflecting a refreshed timeline.SummaryDifference0.2%

- Check71 days agoChange DetectedRecruitment messaging now shows 'No longer looking for participants', the treatment label is standardized to 'Intervention/Treatment' (replacing 'Intervention / Treatment'), several help/navigation links were added (How to Read a Study Record, Common Questions, How to Join a Study), and the revision badge updates from v3.5.4 to v3.6.0.SummaryDifference0.2%

Stay in the know with updates to Zolbetuximab in CLDN18.2+ Gastric Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Zolbetuximab in CLDN18.2+ Gastric Cancer Clinical Trial page.